Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Unresectable or Metastatic Melanoma in India.

NCT07459543 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07459543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07459543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Unresectable or Metastatic Melanoma in India.
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
May 28, 2029
Enrollment
40 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, unresectable melanoma